Detalhe da pesquisa
1.
Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia.
Blood
; 138(21): 2138-2142, 2021 11 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34499715
2.
Treatment of an acquired Factor XIII inhibitor in an adolescent with systemic lupus erythematosus and renal failure.
Transfusion
; 57(9): 2159-2163, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28707410
3.
Repurposing Atovaquone as a Therapeutic against Acute Myeloid Leukemia (AML): Combination with Conventional Chemotherapy Is Feasible and Well Tolerated.
Cancers (Basel)
; 15(4)2023 Feb 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36831684
4.
Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia.
J Clin Oncol
; 41(2): 354-363, 2023 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36108252
5.
Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium.
Blood Adv
; 7(4): 541-548, 2023 02 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35938863
6.
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy.
Blood Adv
; 6(7): 1961-1968, 2022 04 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34788386
7.
Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report.
Blood Adv
; 6(2): 600-610, 2022 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34794180
8.
Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report.
J Clin Oncol
; 40(9): 945-955, 2022 03 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34882493
9.
Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia.
Blood Adv
; 6(14): 4251-4255, 2022 07 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-35580324
10.
Investigational treatment options in phase I and phase II trials for relapsed or refractory acute lymphoblastic leukemia in pediatric patients.
Expert Opin Investig Drugs
; 30(6): 611-620, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33896328
11.
Enhancement of cisplatin [cis-diammine dichloroplatinum (II)] cytotoxicity by O6-benzylguanine involves endoplasmic reticulum stress.
J Pharmacol Exp Ther
; 327(2): 442-52, 2008 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-18664592
12.
Molecular mechanisms of resistance and toxicity associated with platinating agents.
Cancer Treat Rev
; 33(1): 9-23, 2007 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-17084534
13.
Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy.
Cancer Treat Rev
; 32(4): 261-76, 2006 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-16698182
14.
Role of GADD34 in modulation of cisplatin cytotoxicity.
Biochem Pharmacol
; 71(3): 239-47, 2006 Jan 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-16325149
15.
FLT3-IRAK dual targeting: an exciting new therapeutic option guided by adaptive activation of immune response pathways.
Ann Transl Med
; 8(7): 511, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-32395555
16.
Role of copper transporters in resistance to platinating agents.
Cancer Chemother Pharmacol
; 64(1): 133-42, 2009 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-18998134
17.
Platinum pathway.
Pharmacogenet Genomics
; 19(7): 563-4, 2009 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-19525887